Debts to Book Capitalization: Adlai Nortye Ltd (ANL)

Corporate emblem and logo of Adlai Nortye (ANL)

Adlai Nortye Ltd. develops precision methods for combating advanced cancer, leveraging the drug buparlisib. The total debt-to-equity ratio visualizes the debt load, where the value 0.13 represents the latest figure. Risks are increasing due to the dependence on a single candidate and global competition with Western players amid geopolitical barriers.

ANL Adlai Nortye Limited: Debt to Net Assets Ratio in the range 02/21/2024 - 10/30/2026
Product sample of Adlai Nortye Ltd

Adlai Nortye Ltd. (ANL) is developing oncology biotech within the complexities of the Chinese jurisdiction. This indicator compares total debt obligations against balance sheet equity to assess financial leverage. By analyzing the debt-to-equity ratio, an investor can discern the actual credit load without quarterly distortions. Reducing leverage mitigates overpayment risks but limits investments in global clinical trials. An optimal balance of borrowed funds confirms the fundamental stability of the management.

Key competitors

Debts to Book Capitalization ONC (BeiGene Ltd)|HALO - Debt to Book Value|Revolution Medicines, Inc. - Debts to Book Capitalization|Debts to Book Value Ascentage Pharma Group International|CG Oncology Corp (CGON) - Debt to Book Capitalization Ratio|UroGen Pharma Corp - Debt to Net Assets Ratio|Debt to Book Value BCAX|PSNL: Debt to Net Assets Ratio|Debts to Book Capitalization ERAS|Debt to Book Value Delcath Systems Inc DCTH|YmAbs - Debt to Book Value|Debts to Book Capitalization Aura Corp AURA|CADL - Debt to Book Capitalization Ratio|Debt to Net Assets Ratio ARAY (accuray.com)|SLS: Debts to Book Capitalization|Debts to Book Value Actuate Therapeutics Inc. (ACTU)|CTOR (Citius Oncology, Inc) - Debts to Book Capitalization|Debts to Book Capitalization TuHURA|Debts to Book Capitalization TARA|fatetherapeutics.com - Debt to Book Value Ratio|Debt to Book Capitalization Ratio Aadi Bioscience WHWK|TScan Therapeutics Inc - Debt to Book Capitalization Ratio|Champions Oncology Corp - Debts to Book Capitalization|XBIT - Debts to Book Capitalization|CVM: Debts to Book Capitalization|OSTX - Debts to Net Assets|Debt to Book Value RADX|ARTV: Debt to Net Assets Ratio|Debt to Book Capitalization Ratio Veru Pharma (VERU)|Tempest Therapeutics Corp - Debt to Book Value Ratio|Debt to Book Capitalization Ratio Xilio Therapeutics XLO|Renovaro Biosciences (RENB) - Debts to Book Value|MURA - Debt to Book Capitalization Ratio|Debt to Net Assets Ratio KAPA (Kairos Pharma Ltd)|OKUR (onkuretherapeutics.com) - Debt to Book Value|GDTC: Debt to Book Capital|Debt to Book Value CRIS|Debts to Book Value Apollomics Corp APLM|Debts to Book Capitalization THAR|ADVB - Debts to Book Value|Genprex, Inc - Debt to Book Value|Debt to Net Assets Ratio CLDI|SBFM - Debt to Book Capitalization Ratio|XBIO: Debt to Book Capitalization Ratio|SLRX (Salarius Pharmaceuticals, Inc.) - Debt to Book Value|PPBT: Debt to Book Capital|AONC (American Oncology Network Inc) - Debts to Book Capitalization|Debt to Book Value Ratio BGNE (BeiGene Ltd)|Debt to Book Value CKPT (Checkpoint Therapeutics)|Debts to Net Assets elevationoncology.com|Debts to Book Capitalization ICAD (iCAD)|Debts to Book Capitalization Ikena Oncology Inc. IKNA|NTBL - Debt to Book Capitalization Ratio|VIRX (Viracta Therapeutics) - Debt to Book Value Ratio|MorphoSys AG (MOR) - Debt to Book Capitalization Ratio|NAYA (nayabiosciences.com) - Debt to Book Capitalization Ratio|AAPGV (Ascentage Pharma) - Debts to Book Capitalization